High-dose cyclosporin with etoposide - toxicity and pharmacokinetic interaction in children with solid tumours
1998

High-dose cyclosporin with etoposide in children with solid tumours

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): G Bisognol, F Cowie, A Boddy, HD Thomas, G Dick, CR Pinkerton

Primary Institution: Royal Marsden NHS Trust/Institute of Cancer Research

Hypothesis

Can high-dose cyclosporin enhance the effectiveness of etoposide in treating children with recurrent or refractory solid tumours?

Conclusion

The combination of high-dose cyclosporin and etoposide may enhance drug sensitivity in children with solid tumours, but the etoposide dose should be halved to avoid toxicity.

Supporting Evidence

  • Four patients achieved a partial response to the treatment.
  • Significant hypertension was observed in six courses.
  • Hyperbilirubinaemia was present in 25 of 32 courses but was of short duration.
  • Acute toxicity was less common with the continuous infusion compared to the shorter regimen.

Takeaway

This study tested a new treatment for kids with tough cancers by using a special medicine called cyclosporin to help another medicine, etoposide, work better.

Methodology

Eighteen children with recurrent or refractory tumours were treated with high-dose cyclosporin and etoposide, with pharmacokinetic profiles assessed.

Limitations

The study was small and focused primarily on toxicity rather than effectiveness.

Participant Demographics

Participants were children aged 4.4 to 20.7 years, with a median age of 13.6 years; 13 were male.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication